Literature DB >> 21042923

Evaluation of risk factors for the development of cirrhosis in autoimmune hepatitis: Japanese NHO-AIH prospective study.

Kiyoshi Migita1, Yukio Watanabe, Yuka Jiuchi, Yoko Nakamura, Akira Saito, Michiyasu Yagura, Hideo Morimoto, Masaaki Shimada, Eiji Mita, Taizo Hijioka, Haruhiro Yamashita, Eiichi Takezaki, Toyokichi Muro, Hironori Sakai, Makoto Nakamuta, Seigo Abiru, Koji Yano, Atsumasa Komori, Hiroshi Yatsuhashi, Minoru Nakamura, Hiromi Ishibashi.   

Abstract

Autoimmune hepatitis (AIH) is a chronic and progressive liver disease characterized by histological interface hepatitis and circulating autoantibodies. Our aims were to evaluate risk factors that contribute to the outcome and, particularly, the development of liver cirrhosis in a prospective multicenter cohort study of AIH. One hundred and seventy-four patients were enrolled. Histologically 21 (12.1%) had cirrhosis at the initial observation and the remaining 153 showed chronic or acute hepatitis at presentation. Among the latter 153 patients, 14 developed cirrhosis during the follow-up period (mean 8.0 years). Demographic, clinical, and laboratory indices associated with the development of cirrhosis were identified. Patients who developed cirrhosis differed in mean levels of alanine aminotransferase (ALT; 158 ± 182 vs. 441 ± 423 IU/ml) and platelet counts (14.7 ± 5.5 vs. 19.4 ± 6.9 × 10(4)/μl) at presentation and received lower doses of corticosteroid (13.9 ± 15.8 vs. 31.8 ± 85.5 mg/day). In a multivariate analysis, an independent predictor for progression to cirrhosis was an older age of onset (≥ 60 years). AIH patients with cirrhosis, or those who developed cirrhosis, had a worse survival. AIH patients with an older age of onset were likely to develop cirrhosis, and careful observation and aggressive treatments are necessary for such patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21042923     DOI: 10.1007/s00535-010-0337-y

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  20 in total

1.  Mechanisms and implications of the age-associated decrease in DNA repair capacity.

Authors:  D Goukassian; F Gad; M Yaar; M S Eller; U S Nehal; B A Gilchrest
Journal:  FASEB J       Date:  2000-07       Impact factor: 5.191

2.  Diagnosis and management of autoimmune hepatitis.

Authors:  Michael P Manns; Albert J Czaja; James D Gorham; Edward L Krawitt; Giorgina Mieli-Vergani; Diego Vergani; John M Vierling
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

3.  Diagnosing autoimmune hepatitis in nonalcoholic fatty liver disease: is the International Autoimmune Hepatitis Group scoring system useful?

Authors:  Satoru Yatsuji; Etsuko Hashimoto; Hiroyuki Kaneda; Makiko Taniai; Katsutoshi Tokushige; Keiko Shiratori
Journal:  J Gastroenterol       Date:  2005-12       Impact factor: 7.527

Review 4.  Immune-mediated liver injury.

Authors:  Bertus Eksteen; Simon C Afford; Stephen J Wigmore; Andrew P Holt; David H Adams
Journal:  Semin Liver Dis       Date:  2007-11       Impact factor: 6.115

5.  Clinical characteristics of autoimmune hepatitis in older aged patients.

Authors:  Teruki Miyake; Hiroaki Miyaoka; Masanori Abe; Shinya Furukawa; Shuichiro Shigematsu; Eri Furukawa; Rie Ikeda; Shunnji Okita; Takeshi Okada; Osamu Yoshida; Yosuke Murata; Sk Md Fazle Akbar; Bunzo Matsuura; Kojiro Michitaka; Norio Horiike; Yoichi Hiasa; Morikazu Onji
Journal:  Hepatol Res       Date:  2006-07-26       Impact factor: 4.288

6.  International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis.

Authors:  F Alvarez; P A Berg; F B Bianchi; L Bianchi; A K Burroughs; E L Cancado; R W Chapman; W G Cooksley; A J Czaja; V J Desmet; P T Donaldson; A L Eddleston; L Fainboim; J Heathcote; J C Homberg; J H Hoofnagle; S Kakumu; E L Krawitt; I R Mackay; R N MacSween; W C Maddrey; M P Manns; I G McFarlane; K H Meyer zum Büschenfelde; M Zeniya
Journal:  J Hepatol       Date:  1999-11       Impact factor: 25.083

Review 7.  Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications.

Authors:  Scott L Friedman
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2004-12

8.  Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly.

Authors:  Albert J Czaja; Herschel A Carpenter
Journal:  Hepatology       Date:  2006-03       Impact factor: 17.425

9.  Type 1 autoimmune hepatitis and adipokines: new markers for activity and disease progression?

Authors:  Marilena Durazzo; Grazia Niro; Alberto Premoli; Enrico Morello; Erik Rosa Rizzotto; Roberto Gambino; Simona Bo; Giovanni Musso; Maurizio Cassader; Gianfranco Pagano; Annarosa Floreani
Journal:  J Gastroenterol       Date:  2009-03-20       Impact factor: 7.527

Review 10.  Immune interactions in hepatic fibrosis.

Authors:  Andrew P Holt; Mike Salmon; Christopher D Buckley; David H Adams
Journal:  Clin Liver Dis       Date:  2008-11       Impact factor: 6.126

View more
  10 in total

1.  Clinical features of hepatocellular carcinoma in patients with autoimmune hepatitis in Japan.

Authors:  Hiromasa Ohira; Kazumichi Abe; Atsushi Takahashi; Mikio Zeniya; Takafumi Ichida
Journal:  J Gastroenterol       Date:  2012-06-13       Impact factor: 7.527

2.  Aspartate Aminotransferase to Platelet Ratio Index and Fibrosis-4 Index for Detecting Liver Fibrosis in Patients With Autoimmune Hepatitis: A Meta-Analysis.

Authors:  Bingtian Dong; Yuping Chen; Guorong Lyu; Xiaocen Yang
Journal:  Front Immunol       Date:  2022-05-18       Impact factor: 8.786

3.  Association of a single nucleotide polymorphism in TNIP1 with type-1 autoimmune hepatitis in the Japanese population.

Authors:  Shomi Oka; Takashi Higuchi; Hiroshi Furukawa; Minoru Nakamura; Atsumasa Komori; Seigo Abiru; Shinya Nagaoka; Satoru Hashimoto; Atsushi Naganuma; Noriaki Naeshiro; Kaname Yoshizawa; Masaaki Shimada; Hideo Nishimura; Minoru Tomizawa; Masahiro Kikuchi; Fujio Makita; Haruhiro Yamashita; Keisuke Ario; Hiroshi Yatsuhashi; Shigeto Tohma; Aya Kawasaki; Naoyuki Tsuchiya; Kiyoshi Migita
Journal:  J Hum Genet       Date:  2018-03-20       Impact factor: 3.172

4.  The Management of Autoimmune Hepatitis Patients with Decompensated Cirrhosis: Real-World Experience and a Comprehensive Review.

Authors:  Zhaoyue Wang; Li Sheng; Yue Yang; Fan Yang; Xiao Xiao; Jing Hua; Canjie Guo; Yiran Wei; Ruqi Tang; Qi Miao; Jun Zhang; Yanmei Li; Jingyuan Fang; Dekai Qiu; Edward L Krawitt; Christopher L Bowlus; M Eric Gershwin; Qixia Wang; Xiong Ma
Journal:  Clin Rev Allergy Immunol       Date:  2017-06       Impact factor: 8.667

5.  Autoimmune Hepatitis-related Cirrhosis: Clinical Features and Effectiveness of Immunosuppressive Treatment in Chinese Patients.

Authors:  Yan-Ni Li; Huan Ma; Lu Zhou; Jie Zhang; Li-Ping Guo; Shu-Qian Li; Yi-Qi Qian; Bang-Mao Wang
Journal:  Chin Med J (Engl)       Date:  2016-10-20       Impact factor: 2.628

6.  Role of deleterious single nucleotide variants in the coding regions of TNFAIP3 for Japanese autoimmune hepatitis with cirrhosis.

Authors:  Takashi Higuchi; Shomi Oka; Hiroshi Furukawa; Minoru Nakamura; Atsumasa Komori; Seigo Abiru; Satoru Hashimoto; Masaaki Shimada; Kaname Yoshizawa; Hiroshi Kouno; Atsushi Naganuma; Keisuke Ario; Toshihiko Kaneyoshi; Haruhiro Yamashita; Hironao Takahashi; Fujio Makita; Hiroshi Yatsuhashi; Hiromasa Ohira; Kiyoshi Migita
Journal:  Sci Rep       Date:  2019-05-28       Impact factor: 4.379

7.  Serum cytokine profiles and Mac-2 binding protein glycosylation isomer (M2BPGi) level in patients with autoimmune hepatitis.

Authors:  Kiyoshi Migita; Yoshiro Horai; Hideko Kozuru; Tomohiro Koga; Seigo Abiru; Kazumi Yamasaki; Atsumasa Komori; Yuya Fujita; Tomoyuki Asano; Shuzo Sato; Eiji Suzuki; Naoki Matsuoka; Hiroko Kobayashi; Hiroshi Watanabe; Atsushi Naganuma; Noriaki Naeshiro; Kaname Yoshizawa; Hajime Ohta; Hironori Sakai; Masaaki Shimada; Hideo Nishimura; Minoru Tomizawa; Keisuke Ario; Haruhiro Yamashita; Hiroshi Kamitsukasa; Hiroshi Kohno; Minoru Nakamura; Hiroshi Furukawa; Atsushi Takahashi; Atsushi Kawakami; Hiromasa Ohira; Hiroshi Yastuhashi
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

8.  Galectin-9 in autoimmune hepatitis: Correlation between serum levels of galectin-9 and M2BPGi in patients with autoimmune hepatitis.

Authors:  Naoki Matsuoka; Hideko Kozuru; Tomohiro Koga; Seigo Abiru; Kazumi Yamasaki; Atsumasa Komori; Yuya Fujita; Junpei Tenmoku; Tomoyuki Asano; Shuzo Sato; Eiji Suzuki; Makiko Furuya; Hiroko Kobayashi; Hiroshi Watanabe; Atsushi Naganuma; Kaname Yoshizawa; Masaaki Shimada; Keisuke Ario; Haruhiro Yamashita; Hiroshi Kohno; Toshihiko Kaneyoshi; Minoru Nakamura; Hiroshi Furukawa; Atsushi Takahashi; Atsushi Kawakami; Hiromasa Ohira; Hiroshi Yatsuhashi; Kiyoshi Migita
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

Review 9.  Genetic risk factors for autoimmune hepatitis: implications for phenotypic heterogeneity and biomarkers for drug response.

Authors:  Takashi Higuchi; Shomi Oka; Hiroshi Furukawa; Shigeto Tohma; Hiroshi Yatsuhashi; Kiyoshi Migita
Journal:  Hum Genomics       Date:  2021-01-28       Impact factor: 4.639

Review 10.  Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode.

Authors:  Magd A Kotb
Journal:  Int J Mol Sci       Date:  2012-07-17       Impact factor: 6.208

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.